BiotechTube

rLP2086

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Meningitis, Meningococcal, Serogroup B

Conditions

Meningitis, Meningococcal, Serogroup B

Trial Timeline

Feb 1, 2013 → Feb 1, 2014

NCT ID
NCT01768117

About rLP2086

rLP2086 is a phase 2 stage product being developed by Pfizer for Meningitis, Meningococcal, Serogroup B. The current trial status is completed. This product is registered under clinical trial identifier NCT01768117. Target conditions include Meningitis, Meningococcal, Serogroup B.

What happened to similar drugs?

2 of 20 similar drugs in Meningitis, Meningococcal, Serogroup B were approved

Approved (2) Terminated (0) Active (18)
🔄RotaTeq® + NeisVac-C®MerckPhase 3
🔄Meningococcal ACWY conjugate vaccineNovartisPhase 3
✅Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine + MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus VaccineNovartisApproved
🔄Meningococcal ACWY Conjugate Vaccine + DTaP-IPV-HBV + Hib + Rotavirus + Pneumococcal 7-valent Conjugate Vaccine + HAV + MMR-V + DTaPNovartisPhase 3
🔄Meningococcal (Groups A, C, Y and W-135) Conjugate + Meningococcal polysaccharide A, C, Y and W135 and MenveoNovartisPhase 3
🔄Meningococcal ACWY conjugate vaccineNovartisPhase 3
🔄Hib-CRM197 + Hib-TTNovartisPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT01352845Phase 3Completed
NCT01768117Phase 2Completed

Competing Products

20 competing products in Meningitis, Meningococcal, Serogroup B

See all competitors
ProductCompanyStageHype Score
RotaTeq® + NeisVac-C®MerckPhase 3
40
DaptomycinMerckPre-clinical
18
Meningococcal ACWY conjugate vaccineNovartisPhase 3
40
Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine + MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus VaccineNovartisApproved
43
Meningococcal ACWY Conjugate Vaccine + DTaP-IPV-HBV + Hib + Rotavirus + Pneumococcal 7-valent Conjugate Vaccine + HAV + MMR-V + DTaPNovartisPhase 3
40
Meningococcal (Groups A, C, Y and W-135) Conjugate + Meningococcal polysaccharide A, C, Y and W135 and MenveoNovartisPhase 3
40
Meningococcal ACWY conjugate vaccineNovartisPhase 3
40
MenACWY-CRM + MenC-CRM + DTaP-Hib-IPV + PC7 + MMR + VaricellaNovartisPhase 2
35
Hib-CRM197 + Hib-TTNovartisPhase 3
40
Novartis Meningococcal ACWY Conjugate Vaccine + Tdap Vaccine + Novartis Meningococcal ACWY Conjugate VaccineNovartisPhase 3
40
MenACWY-CRM conjugate vaccine, adjuvanted + MenACWY polysaccharide vaccine + MenACWY-CRM conjugate vaccine, unadjuvantedNovartisPhase 2
35
meningococcal B vaccine & meningococcal ACYW conjugate vaccineNovartisPhase 2
35
Efungumab (Mycograb) + placebo + Amphotericin B + 5 flucytosineNovartisPhase 2
27
4CMenBNovartisApproved
43
Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccineNovartisPhase 3
40
Meningococcal (group B) multicomponent recombinant adsorbed vaccineNovartisPhase 3
40
MenACWY-CRM197 (two doses) + MenC + PCV7 + DTPa-IPV-HepB-Hib + MenACWY-CRM197 (one dose)NovartisPhase 3
40
MenACWY-CRM197 + DTaP (Diptheria, Tetanus, Pertussis) Vaccine + Hib (Haemophilus influenza b) Vaccine + IPV (Inactivated Polio Vaccine) Vaccine + Pneumococcal conjugate Vaccine + MMR (Measles, Mumps, and Rubella) Vaccine + Varicella Vaccine + Hepatitis A VirusNovartisPhase 3
40
Meningococcal ACWY Polysaccharide Vaccine + MenACWY CRM (19 to 55 years) + Meningococcal ACWY Conjugate Vaccine + Novartis MenACWY Vaccine (56 to 65 Years)NovartisPhase 3
40
Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Control + Meningococcal B vaccine with antipyreticNovartisPhase 2
35